Vitor Hugo Luna Rocha de Almeida

Instituição:

Universidade Federal do Rio de Janeiro

Centro:

Centro de Ciências da Saúde

Unidade:

Instituto de Bioquímica Médica

Departamento:

Direção Adjunta de Gestão Administrativa/IBqM

Universidade Federal do Rio de Janeiro
Química Biológica | Doutorado | 2013 - 2018

Instituto Federal de Educação, Ciência e Tecnologia do Rio de Janeiro
Biotecnologia | Ensino Profissional de nível técnico | 2003 - 2005

Instituto Federal de Educação, Ciência e Tecnologia do Rio de Janeiro
| Ensino Médio (2o grau) | 2003 - 2005

Nenhum laboratório cadastrado

(94.74% artigos com DOI)

Exibir resultado(s)

Buscar

Titulo	DOI	Ano
Breast-cancer extracellular vesicles induce platelet activation and aggregation by tissue factor-independent and -dependent mechanisms	10.1016/j.thromres.2017.09.019	2017
Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells	10.1038/sj.bjc.6605216	2009
Crosstalk between BCR-ABL and protease-activated receptor 1 (PAR1) suggests a novel target in chronic myeloid leukemia	10.1016/j.exphem.2018.07.008	2018
Different antiproliferative effects of matuzumab and cetuximab in A431 cells are associated with persistent activity of the MAPK pathway	10.1016/j.ejca.2008.12.012	2009
Efficient Blockade of Akt signaling is a determinant factor to overcome resistance to Matuzumab	10.1186/1476-4598-10-151	2011
Epidermal growth factor receptor regulates fibrinolytic pathway elements in cervical cancer: functional and prognostic implications	10.1590/1414-431x202010754	2021
Interplay Between EGFR and the Platelet-Activating Factor/PAF Receptor Signaling Axis Mediates Aggressive Behavior of Cervical Cancer	10.3389/fonc.2020.557280	2020
Neutrophil Extracellular Traps (NETs) Promote Pro-Metastatic Phenotype in Human Breast Cancer Cells through Epithelial-Mesenchymal Transition	10.3390/cancers12061542	2020
Novel Aspects of Extracellular Vesicles as Mediators of Cancer-Associated Thrombosis	10.3390/cells8070716	2019
Novos fármacos com alvo molecular específico em oncologia		2011

Exibindo 1 a 10 de 19 resultados

(5.56% eventos com DOI)

Exibir resultado(s)

Buscar

Titulo	DOI	Ano
A new therapeutic strategy for the treatment of cervical cancer: a study based on human cell lines		2007
Analysis of the crosstalk between EGF receptor and the PAF signaling pathway in cervical cancer		2019
Combination of cetuximab with cisplatin and radiation therapy may have useful applications for the treatment of cervical cancer		2008
Correlation between ATP7A, XIAP and p-AKT expression and cisplatin resistance in non-small cell lung cancer		2011
Correlation between XIAP, pAkt, and ATP7A expression and cisplatin resistance in non-small cell lung cancer		2012
CROSSTALK BETWEEN EPIDERMAL GROWTH FACTOR RECECPTOR (EGFR) AND PROSTAGLANDIN E2 (PGE2): A POSSIBLE LINK BETWEEN CERVICAL CANCER AND INFLAMMATION?		2022
CROSSTALK BETWEEN EPIDERMAL GROWTH FACTOR RECECPTOR (EGFR) AND TF/FVIIa/PAR2 PATHWAY MEDIATES CHEMOTHERAPY RESISTANCE IN CERVICAL CANCER		2017
Crosstalk between Epidermal Growth Factor Receptor (EGFR) and TF/FVIIa/PAR -2 pathway mediates chemotherapy resistance in cervical cancer	10.3252/pso.eu.ISTH2017.2017	2017
Differences in activity between matuzumab and cetuximab in A431 cells may rely on MAPK cascade inhibition		2007
Differences in activity between Matuzumab and Cetuximab in A431 cells may rely on MAPK cascade inhibition		2007

Exibindo 1 a 10 de 36 resultados